ANNX vs. TBPH, ENTA, PLRX, AKRO, MORF, SNDX, HRMY, NAMS, KROS, and GPCR
Should you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Theravance Biopharma (TBPH), Enanta Pharmaceuticals (ENTA), Pliant Therapeutics (PLRX), Akero Therapeutics (AKRO), Morphic (MORF), Syndax Pharmaceuticals (SNDX), Harmony Biosciences (HRMY), NewAmsterdam Pharma (NAMS), Keros Therapeutics (KROS), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical preparations" industry.
Annexon (NASDAQ:ANNX) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.
Annexon has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500.
99.1% of Theravance Biopharma shares are held by institutional investors. 12.7% of Annexon shares are held by company insiders. Comparatively, 6.9% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Annexon has a net margin of 0.00% compared to Theravance Biopharma's net margin of -72.79%. Theravance Biopharma's return on equity of -18.97% beat Annexon's return on equity.
Theravance Biopharma received 293 more outperform votes than Annexon when rated by MarketBeat users. However, 73.33% of users gave Annexon an outperform vote while only 63.47% of users gave Theravance Biopharma an outperform vote.
Theravance Biopharma has higher revenue and earnings than Annexon. Theravance Biopharma is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
In the previous week, Theravance Biopharma had 5 more articles in the media than Annexon. MarketBeat recorded 8 mentions for Theravance Biopharma and 3 mentions for Annexon. Annexon's average media sentiment score of 0.71 beat Theravance Biopharma's score of 0.21 indicating that Annexon is being referred to more favorably in the media.
Annexon presently has a consensus target price of $15.33, indicating a potential upside of 217.46%. Theravance Biopharma has a consensus target price of $20.50, indicating a potential upside of 137.82%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Theravance Biopharma.
Summary
Annexon and Theravance Biopharma tied by winning 8 of the 16 factors compared between the two stocks.
Get Annexon News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
